Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC) (Frankfurt: 3CM) (OTC:CANVF), a leading digital cannabis education and analytics company, is pleased to appoint Brad Poulos to its Educational Advisory Board. Mr. Poulos is currently on faculty and teaching the Business of Cannabis at the Ted Rogers School of Management at Toronto’s Ryerson University, and an in-demand public speaker on the topics of business and the cannabis industry. Mr. Poulos will provide independent oversight and guidance for content on the Cannvas.Me educational platform.

“Brad is an exceptional educator and successful entrepreneur, and we will lean on his expertise and acumen in business, cannabis and higher education circles to elevate the quality and substance of our content on Cannvas.Me,” said Daniel Davidzon, Director of Strategy and Education, Cannvas MedTech. “A seasoned professional and sought-after industry expert across several sectors, Brad’s experience in building and delivering the Business of Cannabis course at Ryerson University will be invaluable as we expand the educational offerings on Cannvas.Me.”


At The Ted Rogers School of Management, in collaboration with Ryerson University’s Chang School of Continuing Education, Mr. Poulos, a 10-year veteran lecturer in entrepreneurship strategy, launched an introductory course called “The Business of Cannabis” after having spent several years researching the industry. Though Ryerson is currently the only university to offer a business course on cannabis in Ontario, Durham College offers a specialization certificate on the cannabis industry taught by another member of the Cannvas Education Advisory Board, Ms. Angela Smith, PhD.

With over 30 years experience across a range of industries including education, cannabis, telecommunications and software, Mr. Poulos has focused on running and advising companies with issues related to growth and business development, optimization and strategy. He currently sits on the Boards of two other companies: Budtender, an industry-leading cannabis customer experience platform, and AXSource, a global regulatory & quality consulting firm. A former profit 100 CEO and public company chair, his unique insights and analysis are in constant demand for media and speaking opportunities.

Members of the Cannvas Medical, Educational and Cannabis Sciences Advisory Board offer independent oversight and guidance to the Cannvas.Me digital cannabis education platform, helping craft and curate original content for cannabis-curious Canadians looking to learn more about all aspects of the plant.

About Cannvas
Cannvas is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation.

Source: www.newswire.ca

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less